Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
WARREN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Holding Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, congratulates Professor Sten Vermund, MD, PhD, Chairperson of Tevogen Bio’s Innovation and Public Health Advisory Board, on being named as the dean of the USF Health College of Public Health, effective January 1, 2025.
In addition to his new role at the University of South Florida, Dr. Vermund will continue to serve as the President of the Global Virus Network (GVN), a nonprofit coalition of human and animal virologists from more than 80 centers of excellence in 40 countries. Under his leadership, the GVN is at the forefront of combating future pandemic threats through cutting-edge research and the development of innovative drugs, vaccines, and treatments.
“The team at Tevogen Bio is honored to have Dr. Vermund as a key advisor and takes immense pride in his recent appointment. His new role at USF highlights his exceptional contributions to public health and his unwavering dedication to advancing global health initiatives,” commented Ryan Saadi, MD, MPH, Founder and CEO, Tevogen Bio.
Sharing his thoughts on his new appointment, Dr. Vermund said “My time as Dean of the Yale School of Public Health was both productive and gratifying. Our alumni played a vital role in supporting us, with Dr. Ryan Saadi at the forefront. When the Global Virus Network relocated its global headquarters to Tampa, an opportunity to move to the University of South Florida presented itself. I saw exciting new opportunities at the USF Health College of Public Health, a public institution that is innovating at many levels.”
About Tevogen Bio
Tevogen is a clinical-stage specialty immunotherapy company harnessing one of nature’s most powerful immunological weapons, CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the significant unmet needs of large patient populations. Tevogen Leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-concept clinical trial, and its key intellectual property assets are wholly owned by the company, not subject to any third-party licensing agreements. These assets include three granted patents, nine pending US and twelve ex-US pending patents, two of which are related to artificial intelligence.
Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation.
Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com
